Animal models of parkinson's disease

Neurodegenerative Diseases

Volumn 2, Issue 6, 2006, Pages 313-320

  Von Bohlen und Halbach, O ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Synuclein; DJ 1; Monkey; Mouse; Striatum; Substantia nigra

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE RECEPTOR STIMULATING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; BRADYKINESIA; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; ENVIRONMENTAL FACTOR; HEREDITY; LEWY BODY; MONKEY; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; RIGIDITY; RODENT; SUBSTANTIA NIGRA; TREMOR; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; GENETICS; HAPLORHINI; HUMAN; METABOLISM; MOUSE; PATHOLOGY; TRANSGENIC MOUSE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINE AGENTS; HAPLORHINI; HUMANS; MICE; MICE, TRANSGENIC; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY;

EID: 33646462447     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000092318     Document Type: Review

References (72)

1. Riess O, Kruger R: Parkinson's disease - A multifactorial neurodegenerative disorder. J Neural Transm Suppl 1999;56:113-125.
2. Dunnett SB, Bjorklund A: Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature 1999;399:A32-A39.
3. Fornai F, Lenzi P, Gesi M, Ferrucci M, Lazzeri G, Natale G, Ruggieri S, Paparelli A: Recent knowledge on molecular components of Lewy bodies discloses future therapeutic strategies in Parkinson's disease. Curr Drug Target CNS Neurol Disord 2003;2:149-152.
4. Takahashi H, Wakabayashi K: The cellular pathology of Parkinson's disease. Neuropathology 2001;21:315-322.
5. von Bohlen und Halbach O: Synucleins and their relationship to Parkinson's disease. Cell Tissue Res 2004;318:163-174.
6. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M: alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 1998;95:6469-6473.
7. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N: Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998;392:605-608.
8. Chung KK, Zhang Y, Lim KL, Tanaka Y, Huang H, Gao J, Ross CA, Dawson VL, Dawson TM: Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat Med 2001;7:1144-1150.
9. Olanow CW, Tatton WG: Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 1999;22:123-144.
10. Cenci MA, Whishaw IQ, Schallert T: Animal models of neurological deficits: how relevant is the rat? Nat Rev Neurosci 2002;3:574-579.
11. Dauer W, Przedborski S: Parkinson's disease: mechanisms and models. Neuron 2003;39:889-909.
12. von Bohlen und Halbach O, Schober A, Krieglstein K: Genes, proteins, and neurotoxins involved in Parkinson's disease. Prog Neurobiol 2004;73:151-177.
13. Schober A: Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res 2004;318:215-224.
14. Betarbet R, Sherer TB, Greenamyre JT: Animal models of Parkinson's disease. Bioessays 2002;24:308-318.
15. Langston JW, Ballard P, Tetrud JW, Irwin I: Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:979-980.
16. Tetrud JW, Langston JW: Tremor in MPTP-induced parkinsonism. Neurology 1992;42:407-410.
17. Langstom JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D: Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 1999;46:598-605.
18. Nicklas WJ, Vyas I, Heikkila RE: Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci 1985;36:2503-2508.
19. Nicklas WJ, Youngster SK, Kindt MV, Heikkila RE: MPTP, MPP+ and mitochondrial function. Life Sci 1987;40:721-729.
20. Dawson TM: New animal models for Parkinson's disease. Cell 2000;101:115-118.
21. Javitch JA, Snyder SH: Uptake of MPP(+) by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin, MPTP. Eur J Pharmacol 1984;106:455-456.
22. Bezard E, Gross CE, Fournier MC, Dovero S, Bloch B, Jaber M: Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter. Exp Neurol 1999;155:268-273.
23. Reinhard JF Jr, Diliberto EJ Jr, Viveros OH, Daniels AJ: Subcellular compartmentalization of 1-methyl-4-phenylpyridinium with catecholamines in adrenal medullary chromaffin vesicles may explain the lack of toxicity to adrenal chromaffin cells. Proc Natl Acad Sci USA 1987;84:8160-8164.
24. Liu Y, Peter D, Roghani A, Schuldiner S, Prive GG, Eisenberg D, Brecha N, Edwards RH: A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter. Cell 1992;70:539-551.
25. Takahashi N, Miner LL, Sora I, Ujike H, Revay RS, Kostic V, Jackson-Lewis V, Przedborski S, Uhl GR: VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc Natl Acad Sci USA 1997;94:9938-9943.
26. Beal MF: Experimental models of Parkinson's disease. Nat Rev Neurosci 2001;2:325-334.
27. Przedborski S, Jackson-Lewis V, Naini AB, Jakowec M, Petzinger G, Miller R, Akram M: The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J Neurochem 2001;76:1265-1274.
28. Przedborski S, Vila M: The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease. Ann NY Acad Sci 2003;991:189-198.
29. Grunblatt E, Mandel S, Youdim MB: MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson's disease: neuroprotective strategies. J Neurol 2000;247:II95-II102.
30. Schmidt N, Ferger B: Neurochemical findings in the MPTP model of Parkinson's disease. J Neural Transm 2001;108:1263-1282.
31. Giovanni A, Sonsalla PK, Heikkila RE: Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. 2. Central administration of 1-methyl-4-phenylpyridinium. J Pharmacol Exp Ther 1994;270:1008-1014.
32. Giovanni A, Sieber BA, Heikkila RE, Sonsalla PK: Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine. 1. Systemic administration. J Pharmacol Exp Ther 1994;270:1000-1007.
33. Sedelis M, Schwarting RK, Huston JP: Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav Brain Res 2001;125:109-125.
34. Vila M, Vukosavic S, Jackson-Lewis V, Neystat M, Jakowec M, Przedborski S: Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J Neurochem 2000;74:721-729.
35. Meredith GE, Totterdell S, Petroske E, Santa CK, Callison RC Jr, Lau YS: Lysosomal malfunction accompanies alpha-synuclein aggregation in a progressive mouse model of Parkinson's disease. Brain Res 2002;956:156-165.
36. Kuhn K, Wellen J, Link N, Maskri L, Lubbert H, Stichel CC: The mouse MPTP model: gene expression changes in dopaminergic neurons. Eur J Neurosci 2003;17:1-12.
37. Maries E, Dass B, Collier TJ, Kordower JH, Steece-Collier K: The role of alpha-synuclein in Parkinson's disease: insights from animal models. Nat Rev Neurosci 2003;4:727-738.
38. Tatton NA, Kish SJ: In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 1997;77:1037-1048.
39. Jackson-Lewis V, Jakowec M, Burke RE, Przedborski S: Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 1995;4:257-269.
40. Braak H, Braak E, Yilmazer D, de Vos RA, Jansen EN, Bohl J, Jellinger K: Amygdala pathology in Parkinson's disease. Acta Neuropathol (Berl) 1994;88:493-500.
41. Tessitore A, Hariri AR, Fera F, Smith WG, Chase TN, Hyde TM, Weinberger DR, Mattay VS: Dopamine modulates the response of the human amygdala: a study in Parkinson's disease. J Neurosci 2002;22:9099-9103.
42. Whitehouse PJ, Vale WW, Zweig RM, Singer HS, Mayeux R, Kuhar MJ, Price DL, De Souza EB: Reductions in corticotropin releasing factor-like immunoreactivity in cerebral cortex in Alzheimer's disease, Parkinson's disease, and progressive supranuclear palsy. Neurology 1987;37:905-909.
43. Huang CC, Lee EH: Alteration of corticotropin-releasing factor immunoreactivity in MPTP-treated rats. J Neurosci Res 1995;41:471-480.
44. von Bohlen und Halbach O, Schober A, Hertel R, Unsicker K: MPTP treatment impairs tyrosine hydroxylase immunopositive fibers not only in the striatum, but also in the amygdala. Neurodegenerative Dis 2005;2:44-48.
45. Freyaldenhoven TE, Ali SF, Schmued LC: Systemic administration of MPTP induces thalamic neuronal degeneration in mice. Brain Res 1997;759:9-17.
46. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL: Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047.
47. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O: Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998;18:106-108.
48. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, Llorens V, Tortosa EG, Del Ser T, Munoz DG, De Yebenes JG: The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004;55:164-173.
49. Abeliovich A, Schmitz Y, Farinas I, ChoiLundberg D, Ho WH, Castillo PE, Shinsky N, Verdugo JM, Armanini M, Ryan A, Hynes M, Phillips H, Sulzer D, Rosenthal A: Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000;25:239-252.
50. Cabin DE, Shimazu K, Murphy D, Cole NB, Gottschalk W, McIlwain KL, Orrison B, Chen A, Ellis CE, Paylor R, Lu B, Nussbaum RL: Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci 2002;22:8797-8807.
51. Dauer W, Kholodilov N, Vila M, Trillat AC, Goodchild R, Larsen KE, Staal R, Tieu K, Schmitz Y, Yuan CA, Rocha M, Jackson-Lewis V, Hersch S, Sulzer D, Przedborski S, Burke R, Hen R: Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci USA 2002;99:14524-14529.
52. Drolet RE, Behrouz B, Lookingland KJ, Goudreau JL: Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration. Neurotoxicology 2004;25:761-769.
53. Schluter OM, Fornai F, Alessandri MG, Takamori S, Geppert M, Jahn R, Sudhof TC: Role of alpha-synuclein in 1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine-induced parkinsonism in mice. Neuroscience 2003;118:985-1002.
54. Nieto M, Gil-Bea FJ, Dalfo E, Cuadrado M, Cabodevilla F, Sanchez B, Catena S, Sesma T, Ribe E, Ferrer I, Ramirez MJ, Gomez-Isla T: Increased sensitivity to MPTP in human alpha-synuclein A30P transgenic mice. Neurobiol Aging, in press.
55. Dong Z, Ferger B, Feldon J, Bueler H: Overexpression of Parkinson's disease-associated alpha-synuclein A5 3T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP. J Neurobiol 2002;53:1-10.
56. Song DD, Shults CW, Sisk A, Rockenstein E, Masliah E: Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP. Exp Neurol 2004;186:158-172.
57. Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, Dekker MC, Squitieri F, Ibanez P, Joosse M, van Dongen JW, Vanacore N, van Swieten JC, Brice A, Meco G, Van Duijn CM, Oostra BA, Heutink P: Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003;299:256-259.
58. Shang H, Lang D, Jean-Marc B, Kaelin-Lang A: Localization of DJ-1 mRNA in the mouse brain. Neurosci Lett 2004;367:273-277.
59. Kotaria N, Hinz U, Zechel S, von Bohlen und Halbach O: Localization of DJ-1 protein in the murine brain. Cell Tissue Res 2005;322:503-507.
60. Kim RH, Smith PD, Aleyasin H, Hayley S, Mount MP, Pownall S, Wakeham A, You-Ten AJ, Kalia SK, Horne P, Westaway D, Lozano AM, Anisman H, Park DS, Mak TW: Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6- tetrahydropyrindine(MPTP) and oxidative stress. Proc Natl Acad Sci USA 2005;102:5215-5220.
61. Bove J, Prou D, Perier C, Przedborski S: Toxin-induced models of Parkinson's disease. NeuroRx 2005;2:484-494.
62. Eslamboli A: Marmoset monkey models of Parkinson's disease: which model, when and why? Brain Res Bull 2005;68:140-149.
63. Forno LS, Langston JW, DeLanney LE, Irwin I, Ricaurte GA: Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Ann Neurol 1986;20:449-455.
64. Kowall NW, Hantraye P, Brouillet E, Beal MF, McKee AC, Ferrante RJ: MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. Neuroreport 2000;11:211-213.
65. Wakabayashi K, Hayashi S, Kakita A, Yamada M, Toyoshima Y, Yoshimoto M, Takahashi H: Accumulation of alpha-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy. Acta Neuropathol (Berl) 1998;96:445-452.
66. Forno LS, Langston JW, DeLanney LE, Irwin I: An electron microscopic study of MPTP-induced inclusion bodies in an old monkey. Brain Res 1988;448:150-157.
67. Bergman H, Wichmann T, Karmon B, DeLong MR: The primate subthalamic nucleus. 2. Neuronal activity in the MPTP model of parkinsonism. J Neurophysiol 1994;72:507-520.
68. Bergman H, Wichmann T, DeLong MR: Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 1990;249:1436-1438.
69. Struppler A, Lucking CH, Erbel F: Neurophysiological findings during stereotactic operation in thalamus and subthalamus. Confin Neurol 1972;34:70-73.
70. Benabid AL, Pollak P, Louveau A, Henry S, de Rougemont J: Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. Appl Neurophysiol 1987;50:344-346.
71. Krack P, Pollak P, Limousin P, Hoffmann D, Xie J, Benazzouz A, Benabid AL: Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson's disease. Brain 1998;121:451-457.
72. Limousin P, Krack P, Pollak P, Benazzouz A, Ardouin C, Hoffmann D, Benabid AL: Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 1998;339:1105-1111.